The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform
Gaye Usluer - One of the best experts on this subject based on the ideXlab platform.
-
In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates
Mikrobiyoloji Bulteni, 2010Co-Authors: Nayman Alpat S, Askin Derya Aybey, Filiz Aksit, Ilhan Ozgunes, Abdurrahman Kiremitci, Gaye UsluerAbstract:: Acinetobacter baumannii is a frequent cause of nosocomial infections in most hospitals. Management of infections caused by these strains is difficult, as the strains often display multiple drug resistance, including carbapenem. Tigecycline which is a Glycylcycline Derivative has antimicrobial activity against many gram-positive and gram-negative organisms. In this study, in vitro activity of tigecycline and carbapenems against clinical isolates of A.baumannii strains were investigated. A total of 100 A.baumannii isolates were collected from hospitalized patients with documented nosocomial infections [pneumonia (n = 39), surgical wound infection (n = 32), bacteremia (n = 16), catheter infection (n = 6), urinary tract infection (n = 5), peritonitis (n = 1), eye infection (n = 1)] between October 2006 and June 2007. Only one isolate per patient was included to the study. Minimum inhibitory concentrations (MIC) of tigecycline were determined by E-test (AB Biodisk, Sweden). Carbapenem resistance of A.baumannii strains were determined by disk diffusion method. All of the 100 A.baumannii isolates (100%) were found susceptible to tigecycline (MIC values ≤ 2 µg/ml; MIC ranges: 0.032-1.5 µg/ml). Imipenem susceptibility test was performed for 95 strains, and 36 (37.9%) were found sensitive, 18 (18.9%) were intermediate sensitive, and 41 (43.2%) were resistant. Meropenem susceptibility test was performed for 87 strains, and 22 (25.3%) were found sensitive, 9 (10.3%) were intermediate sensitive, and 56 (64.4%) were resistant. Since tigecycline is found quite effective on nosocomial A.baumannii isolates, it may be considered as a treatment alternative in infections caused by carbapenem-resistant Acinetobacter spp.
Nayman Alpat S - One of the best experts on this subject based on the ideXlab platform.
-
In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates
Mikrobiyoloji Bulteni, 2010Co-Authors: Nayman Alpat S, Askin Derya Aybey, Filiz Aksit, Ilhan Ozgunes, Abdurrahman Kiremitci, Gaye UsluerAbstract:: Acinetobacter baumannii is a frequent cause of nosocomial infections in most hospitals. Management of infections caused by these strains is difficult, as the strains often display multiple drug resistance, including carbapenem. Tigecycline which is a Glycylcycline Derivative has antimicrobial activity against many gram-positive and gram-negative organisms. In this study, in vitro activity of tigecycline and carbapenems against clinical isolates of A.baumannii strains were investigated. A total of 100 A.baumannii isolates were collected from hospitalized patients with documented nosocomial infections [pneumonia (n = 39), surgical wound infection (n = 32), bacteremia (n = 16), catheter infection (n = 6), urinary tract infection (n = 5), peritonitis (n = 1), eye infection (n = 1)] between October 2006 and June 2007. Only one isolate per patient was included to the study. Minimum inhibitory concentrations (MIC) of tigecycline were determined by E-test (AB Biodisk, Sweden). Carbapenem resistance of A.baumannii strains were determined by disk diffusion method. All of the 100 A.baumannii isolates (100%) were found susceptible to tigecycline (MIC values ≤ 2 µg/ml; MIC ranges: 0.032-1.5 µg/ml). Imipenem susceptibility test was performed for 95 strains, and 36 (37.9%) were found sensitive, 18 (18.9%) were intermediate sensitive, and 41 (43.2%) were resistant. Meropenem susceptibility test was performed for 87 strains, and 22 (25.3%) were found sensitive, 9 (10.3%) were intermediate sensitive, and 56 (64.4%) were resistant. Since tigecycline is found quite effective on nosocomial A.baumannii isolates, it may be considered as a treatment alternative in infections caused by carbapenem-resistant Acinetobacter spp.
David W. Hecht - One of the best experts on this subject based on the ideXlab platform.
-
Susceptibility Test Methods: Anaerobic Bacteria*
Manual of Clinical Microbiology 10th Edition, 2011Co-Authors: Audrey N. Schuetz, David W. HechtAbstract:This chapter describes the currently available methodologies and their interpretation for susceptibility testing of anaerobes. At present, alternative testing methods include limited agar dilution, broth microdilution (for the B. fragilis group), and the Etest gradient strip method. Tigecycline, a Glycylcycline Derivative of minocycline, was recently introduced for treatment of intra-abdominal and skin and soft tissue infections. Several studies have found very good activity against anaerobes, with rare strains exhibiting tigecycline MICs of >8 µg/ml. Extensive taxonomic changes have occurred within the non-spore-forming gram-positive bacilli, especially with those previously in the genus Eubacterium. It is important to compare the drug-containing plates to the drug-free control plate when reading the tests, as different species of anaerobic bacteria can have very differently appearing spots, ranging from mucoid-opaque, as with the B. fragilis group, to gray-transparent, as with Bacteroides ureolyticus. Broth microdilution MIC determinations require criteria similar to those for the agar dilution procedure for reading end points: the concentration at which the most significant reduction in growth is observed and interpreted as the MIC. Current methodologies allow for accurate surveillance or individual isolate testing by most laboratories. Future studies comparing broth microdilution to the reference agar method and the anticipated development of an improved microdilution system will result in better standardization of the more-user-friendly method and, possibly, more widespread commercial availability.
Filiz Aksit - One of the best experts on this subject based on the ideXlab platform.
-
In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates
Mikrobiyoloji Bulteni, 2010Co-Authors: Nayman Alpat S, Askin Derya Aybey, Filiz Aksit, Ilhan Ozgunes, Abdurrahman Kiremitci, Gaye UsluerAbstract:: Acinetobacter baumannii is a frequent cause of nosocomial infections in most hospitals. Management of infections caused by these strains is difficult, as the strains often display multiple drug resistance, including carbapenem. Tigecycline which is a Glycylcycline Derivative has antimicrobial activity against many gram-positive and gram-negative organisms. In this study, in vitro activity of tigecycline and carbapenems against clinical isolates of A.baumannii strains were investigated. A total of 100 A.baumannii isolates were collected from hospitalized patients with documented nosocomial infections [pneumonia (n = 39), surgical wound infection (n = 32), bacteremia (n = 16), catheter infection (n = 6), urinary tract infection (n = 5), peritonitis (n = 1), eye infection (n = 1)] between October 2006 and June 2007. Only one isolate per patient was included to the study. Minimum inhibitory concentrations (MIC) of tigecycline were determined by E-test (AB Biodisk, Sweden). Carbapenem resistance of A.baumannii strains were determined by disk diffusion method. All of the 100 A.baumannii isolates (100%) were found susceptible to tigecycline (MIC values ≤ 2 µg/ml; MIC ranges: 0.032-1.5 µg/ml). Imipenem susceptibility test was performed for 95 strains, and 36 (37.9%) were found sensitive, 18 (18.9%) were intermediate sensitive, and 41 (43.2%) were resistant. Meropenem susceptibility test was performed for 87 strains, and 22 (25.3%) were found sensitive, 9 (10.3%) were intermediate sensitive, and 56 (64.4%) were resistant. Since tigecycline is found quite effective on nosocomial A.baumannii isolates, it may be considered as a treatment alternative in infections caused by carbapenem-resistant Acinetobacter spp.
Askin Derya Aybey - One of the best experts on this subject based on the ideXlab platform.
-
In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates
Mikrobiyoloji Bulteni, 2010Co-Authors: Nayman Alpat S, Askin Derya Aybey, Filiz Aksit, Ilhan Ozgunes, Abdurrahman Kiremitci, Gaye UsluerAbstract:: Acinetobacter baumannii is a frequent cause of nosocomial infections in most hospitals. Management of infections caused by these strains is difficult, as the strains often display multiple drug resistance, including carbapenem. Tigecycline which is a Glycylcycline Derivative has antimicrobial activity against many gram-positive and gram-negative organisms. In this study, in vitro activity of tigecycline and carbapenems against clinical isolates of A.baumannii strains were investigated. A total of 100 A.baumannii isolates were collected from hospitalized patients with documented nosocomial infections [pneumonia (n = 39), surgical wound infection (n = 32), bacteremia (n = 16), catheter infection (n = 6), urinary tract infection (n = 5), peritonitis (n = 1), eye infection (n = 1)] between October 2006 and June 2007. Only one isolate per patient was included to the study. Minimum inhibitory concentrations (MIC) of tigecycline were determined by E-test (AB Biodisk, Sweden). Carbapenem resistance of A.baumannii strains were determined by disk diffusion method. All of the 100 A.baumannii isolates (100%) were found susceptible to tigecycline (MIC values ≤ 2 µg/ml; MIC ranges: 0.032-1.5 µg/ml). Imipenem susceptibility test was performed for 95 strains, and 36 (37.9%) were found sensitive, 18 (18.9%) were intermediate sensitive, and 41 (43.2%) were resistant. Meropenem susceptibility test was performed for 87 strains, and 22 (25.3%) were found sensitive, 9 (10.3%) were intermediate sensitive, and 56 (64.4%) were resistant. Since tigecycline is found quite effective on nosocomial A.baumannii isolates, it may be considered as a treatment alternative in infections caused by carbapenem-resistant Acinetobacter spp.